



Expanding Indications for Liver Transplant: Tumor and Patient Factors

Kevin Ka-Wan Chu¹, Kelly Hiu-Ching Wong², and Kenneth Siu-Ho Chok³

¹Department of Surgery, ²Li Ka Shing Faculty of Medicine, and ³Department of Surgery and State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China

Article Info

Received July 30, 2019

Revised November 29, 2019

Accepted November 29, 2019

Published online February 28, 2020

Corresponding Author

Kenneth Siu-Ho Chok

ORCID <https://orcid.org/0000-0001-7921-3807>

E-mail kennethchok@gmail.com

During the past few decades, liver transplant has developed from a high-mortality procedure to an almost routine procedure with good survival outcomes. The development of living donor liver transplant has increased the availability of liver grafts, and the scope of indications for liver transplant has been expanding ever since. The aim of this review is to provide an overview of such an expansion of scope. Various criteria have been proposed to expand the eligibility of patients with hepatocellular carcinoma exceeding the Milan criteria for liver transplant. Furthermore, liver transplant is increasingly performed as a treatment modality for cholangiocarcinoma, neuroendocrine liver metastasis and colorectal liver metastasis. The number of elderly patients receiving liver transplant is on the rise. Combined organ transplantation has also been adopted to treat patients with multiple organ failure. Going forward, further development of preoperative noninvasive predictors in tumor, patient and even donor factors is needed to identify patients at risk of poor outcomes and hence optimize patient management. (*Gut Liver* 2021;15:19-30)

Key Words: Liver transplant; Hepatocellular carcinoma; Surgical indication

INTRODUCTION

Liver transplant is one of the most effective treatments for irreversible acute or chronic liver failure and liver diseases with different causes when liver resection is contraindicated. During the past four decades, liver transplant has developed from a high-mortality procedure to an almost routine procedure with good survival outcomes, i.e. >80% at 1 year and >70% at 5 years.^{1,2} At the same time, living donor liver transplant was developed in the background of organ shortage³⁻⁵ and has greatly expanded the availability of liver grafts. With various methods to increase graft availability together with improvement in patient outcomes, the scope of indications for liver transplant is expanding.

Hepatocellular carcinoma (HCC) is the commonest malignant indication for liver transplant. Starzl *et al.*⁶ described the first successful liver transplant as an oncological treatment for hepatoblastoma in 1967. Early attempts at using liver transplant to treat cholangiocarcinoma were disappointing. Better results were reported with more specific patient selection.^{7,8} In the past, metastatic liver dis-

ease was a contraindication to liver transplant. Nowadays, liver transplant for diseases such as neuroendocrine liver metastasis,⁹⁻¹¹ colorectal liver metastasis,^{12,13} etc. is being considered because of the slow-growing nature of these tumors. However, these indications are not favored by the transplant community when the shortage of liver grafts is concerned, especially in Asian places where liver graft shortage is grave (e.g., Hong Kong). In these places, the main concern about offering liver transplant to patients with neuroendocrine or colorectal liver metastasis would be the potential impact on other patients on local liver transplant waiting lists.

Liver transplant is an ultra-major surgery, and hence it was considered to be relatively contraindicated when the patients had high-risk factors for ultra-major surgery.¹⁴ However, with improvement in general outcomes, high-risk patients who have an advanced age, ultra-high Model of End-Stage Liver Disease (MELD) scores or co-morbidities are now potential candidates for liver transplant. In more extreme cases, combined organ transplant is a measure to treat multiple organ failure.¹⁵⁻¹⁷

Copyright © Gut and Liver.



This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

The aim of this review is to give an overview of the expansion of liver transplant indications. In particular, the discussion will focus on the role of tumor factors and patient factors in determining eligibility for liver transplant.

TUMOR FACTORS

1. HCC exceeding the Milan criteria

Since the introduction of the Milan criteria by Mazzaferro *et al.* in 1996,¹⁸ it has been considered the gold standard for selection of HCC patients for liver transplant. The Milan criteria, defined as the presence of a tumor 5 cm or less in patients with single HCCs and no more than three tumor nodules, each 3 cm or less in diameter in patients with multiple tumors, has been validated by numerous studies over the past years. In a meta-analysis performed in 2011 including 19 studies conducted in 15 years on Milan criteria,¹⁹ it was concluded that significantly increased posttransplant survival was expected for patients who met the Milan criteria when compared with those who did not. A hazard ratio of 1.68 confirmed the inferior survival of patients beyond the Milan criteria when compared with patients within the criteria. However, over the past 20 years, the transplant community has come to realize that the Milan criteria are too restrictive, especially in the context of living donor liver transplant. Numerous centers have attempted to expand the Milan criteria through performing liver transplant for patients beyond the Milan criteria and evaluating the outcomes in these patients. These new criteria are summarized in Table 1.

Several groups have proposed new criteria featuring the expansion of the size and number of tumor nodules accepted on the basis of the Milan criteria. The University of California San Francisco (UCSF) criteria are the earliest and most well-known in this category.²⁰ In the study, 70 HCC patients receiving liver transplant were retrospectively analyzed. It was found that patients meeting the criterion of solitary tumor ≤ 6.5 cm or ≤ 3 nodules with the largest lesion ≤ 4.5 cm and total tumor diameter ≤ 8 cm had 1- and 5-year survival rates of 90% and 75.2% respectively; on the other hand, the 1-year survival rate was 50% for patients beyond this criterion. The UCSF criteria were defined on the basis of explant histology findings, so the same group conducted a prospective study to validate the UCSF criteria on the basis of pretransplant imaging.²¹ The UCSF criteria were subsequently validated by Patel *et al.* in 2012.²² It was demonstrated that patients within the Milan criteria and patients within the UCSF criteria had similar overall survival. Thereafter, other criteria including the Hangzhou criteria and the Tokyo criteria were developed

and validated over the years.²³⁻²⁷ The Hangzhou criteria were shown to provide an expansion rate of 51.5% when compared with the Milan criteria, while the overall and tumor-free survival rates were not significantly different.²⁸

Portal vein tumor thrombus (PVTT) has been considered a contraindication to liver transplant due to the high risk of posttransplant intrahepatic recurrence or extrahepatic metastasis.²⁹ However, recent studies in South Korea have expanded the indications for living donor liver transplant to include patients with PVTT.³⁰⁻³² Lee *et al.*³² from Seoul National University Hospital investigated the outcomes of 11 patients diagnosed with HCC and PVTT who had received liver transplant and analyzed the risk factors for recurrence. The 1-, 3-, and 5-year recurrence-free survival rates were 63.3%, 45.5% and 45.5% respectively. Main portal vein invasion and high alpha-fetoprotein \times protein induced by vitamin K absence/antagonist-II (AP score) $\geq 20,000$ were identified as significant risk factors for recurrence. It was therefore suggested that living donor liver transplant can be considered as a curative treatment option for patients with PVTT with careful selection of patients with a low AP score and PVTT not extending to the main portal vein. Similarly, studies from Seoul St. Mary's Hospital³⁰ and Soonchunhyang University Seoul Hospital³¹ also concluded that, with careful selection criteria, living donor liver transplant can be offered to patients with PVTT.

Biochemical parameters such as alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) levels are included in several proposed selection criteria.^{27,33-35} Serum AFP has been increasingly recognized as a marker for poor prognosis after liver transplant. An AFP level $>1,000$ ng/mL has been identified as a surrogate for vascular invasion and significant predictor of HCC recurrence after transplant.³⁶ AFP is therefore incorporated in a few selection criteria including the 5-5-500 rule,³⁵ which defines the eligibility criteria as tumor diameter ≤ 5 cm, tumor number ≤ 5 and serum AFP level ≤ 500 ng/mL. Using the 5-5-500 rule, the study recorded a 5-year recurrence rate of 7.3% (95% confidence interval, 5.2% to 9.3%), and the rule provided a 19% increase in the number of patients eligible for transplant when compared with the Milan criteria. The 5-year overall survival rate was 75.8% for patients within the 5-5-500 rule. The Samsung criteria³⁴ have parameters similar to the 5-5-500 rule but the cutoffs are higher, allowing a maximum tumor size of ≤ 6 cm, tumor number of ≤ 7 and AFP level of $\leq 1,000$ ng/mL. Interestingly, the 1-, 3-, 5-year overall survival rates of patients meeting the Samsung criteria were 97.9%, 91.5% and 90% respectively, which were higher than those reported in the 5-5-500 study despite much more lenient cutoffs. Further research on AFP cutoff level that would optimize patient

Table 1. Expansion in Liver Transplant for HCC Exceeding the Milan Criteria

Strategy	Criteria and validation studies	Key points
The gold standard	Milan criteria ¹⁸ Validation: meta-analysis of 25 studies by Mazzaferro <i>et al.</i> ¹⁹	Single tumor ≤5 cm, or No more than 3 tumor nodules, each ≤3 cm No extrahepatic manifestations No evidence of gross vascular invasion
Expansion in size and number	University of California, San Francisco (UCSF) Criteria ²⁰ Validation: Yao <i>et al.</i> , ²¹ Patel <i>et al.</i> , ²² Unek <i>et al.</i> ¹¹⁴	Solitary tumor ≤6.5 cm, or ≤3 Nodules with the largest lesion ≤4.5 cm and total tumor diameter ≤8 cm
	Hangzhou criteria ²⁷ Validation: Xu <i>et al.</i> ²⁸	One of the following two items; Total tumor diameter ≤8 cm Total tumor diameter >8 cm, with histopathologic grade I or II and preoperative AFP level ≤400 ng/mL, simultaneously
	Tokyo criteria (5-5 rule) ²⁶ Validation: Togashi <i>et al.</i> ¹¹⁵ Asan criteria ²⁴ Validation: Bonadio <i>et al.</i> ¹¹⁶	≤5 Nodules Maximum tumor diameter of 5 cm Largest tumor diameter ≤5 cm HCC number ≤6 No gross vascular invasion
Presence of portal vein invasion	Up-to-seven criteria (new Milan criteria) ²⁵ Validation: de Ataide <i>et al.</i> ¹¹⁷	Size of largest tumor (in cm) plus number of tumors ≤7
	Seoul St. Mary's Hospital ³⁰	Segmental portal vein tumor thrombus is acceptable, especially when AFP <100 ng/mL Lobar portal vein tumor thrombus remains a contraindication to liver transplant
	Seoul National University Hospital ³² Soonchunhyang University Seoul Hospital ³¹	Living donor liver transplant could be considered if - portal vein tumor thrombus does not extend into the main portal vein - AFP×PIVKA-II score is not high (≤20,000) Living donor liver transplant could be considered if - portal vein tumor thrombus is less than Vp4 type (presence of tumor thrombus in the main trunk of the portal vein or a portal vein branch contralateral to the primarily involved lobe, or both) - showed good response to radiotherapy down-staging
Addition of biochemical markers	5-5-500 Rule ³⁵	Nodule size ≤5 cm in diameter Nodule number ≤5 AFP ≤500 ng/mL
	Kyoto criteria ³³ Validation: Kaido <i>et al.</i> ¹¹⁸	≤10 Tumor nodules, and all ≤5 cm, and PIVKA-II ≤400 mAU/mL
	Samsung criteria ³⁴	Maximal tumor size ≤6 cm Tumor number ≤7 AFP levels ≤1,000 ng/mL
Down-staging	Parikh <i>et al.</i> , ³⁷ Lei <i>et al.</i> , ¹¹⁹ Yao <i>et al.</i> ³⁸	The success rate of down-staging to within Milan criteria exceeds 40% ³⁷ Recipients who meet Milan or UCSF criteria after successful down-staging achieve similar results to recipients fulfilling the criteria without down-staging ^{38,119}

HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist-II.

outcomes is required. The Kyoto criteria include PIVKA-II level as part of the criteria as PIVKA-II level >400 mAU/mL has been identified as an independent risk factor for postoperative recurrence.

Down-staging has been proposed as a method to expand the eligibility of HCC patients for liver transplant. Down-staging can be defined as a reduction in tumor burden using locoregional therapy to reduce tumor stage to within eligibility criteria for liver transplant. A meta-anal-

ysis performed by Parikh *et al.*³⁷ reported that the pooled success rate of down-staging was 48% and the pooled post-transplant HCC recurrence rate was 16%. In an intention-to-treat analysis,³⁸ it was found that successful down-staging of HCC to within the Milan criteria resulted in a 5-year survival rate of 77.8%, which is comparable to the 81% reported in patients already within the Milan criteria without down-staging. These results have demonstrated that down-staging may be a potential method to further

expand liver transplant indications in HCC patients beyond defined criteria.

2. Cholangiocarcinoma

Cholangiocarcinoma is a malignant tumor of the biliary system and is the second commonest primary liver cancer after HCC.³⁹ Depending on its location, it can be classified as hilar cholangiocarcinoma, intrahepatic cholangiocarcinoma or distal cholangiocarcinoma (mid-third and lower-third of the bile duct).⁴⁰

Hilar cholangiocarcinoma carries a poor prognosis; the overall survival was reported to be between 12 and 24 months.⁴¹ Although the most promising treatment is complete resection with negative oncological margin, this could only be achieved in one-third of the patients.⁴²⁻⁴⁴ The low resection rate gave rise to the concept of treating these patients with liver transplant, which would be a cure for patients with unresectable hilar cholangiocarcinoma or insufficient liver reserve. However, early attempts of liver transplant alone as treatment of cholangiocarcinoma resulted in disappointing results, with a 5-year survival of 23% to 30% only.^{45,46}

Neoadjuvant therapy before liver transplant has been shown to result in improved survival outcomes. Nebraska University was among the first to offer neoadjuvant therapy to patients with hilar cholangiocarcinoma before liver transplant.⁴⁷ Although the number of patients in the study was small (n=17), this was the first study to report favorable long-term survival in selected patients with unresectable hilar cholangiocarcinoma; 45% of the transplant recipients were alive with a median follow-up period of 7.5 years. The Mayo Clinic group reported their series with neoadjuvant therapy followed by liver transplant in 2000.⁷ This led to the development of the Mayo Clinic protocol, which includes selection of patients without evidence of metastatic or nodal disease, neoadjuvant high-dose radiotherapy, and operative staging followed by liver transplant.⁴⁸ With the neoadjuvant protocol consisting of a combination of external beam and transcatheter radiation with intravenous 5-fluorouracil, only one out of 11 transplant recipients had tumor relapse. It was thus concluded that liver transplant in combination with preoperative irradiation and chemotherapy might be a potential treatment for patients with early-stage cholangiocarcinoma. In an early study comparing liver resection and liver transplant, the 5-year survival rate was 21% in the resection group and 82% in the transplant group with neoadjuvant chemoradiation.⁴⁹ More recent publications from the Mayo Clinic reported 2- and 5-year recurrence-free survival rates of 78% and 65% respectively⁵⁰ with the adoption of the Mayo Clinic protocol. Hong *et al.*⁵¹ identified the lack of neoad-

juvant and adjuvant therapy as an independent predictor of tumor recurrence after liver transplant for cholangiocarcinoma.

The Mayo Clinic protocol has received criticism as it includes two separate components which may affect survival results, namely, strict selection criteria and neoadjuvant therapy. A study by Mantel *et al.*⁵² investigated the effect of strict selection on patient survival. They looked into the survival outcomes in patients who were selected based on the Mayo Clinic protocol and received no neoadjuvant therapy. The 5-year survival of this subgroup of patients was 59%, suggesting that selection criteria alone could result in improved survival when compared with results reported by early studies.

Table 2 is a summary of survival outcomes of liver transplant for hilar cholangiocarcinoma in studies with different neoadjuvant and selection protocols. As shown, combination of strict selection criteria and neoadjuvant therapy may achieve acceptable long-term survival in patients with hilar cholangiocarcinoma. Hence, hilar cholangiocarcinoma should not be an absolute contraindication to liver transplant. However, most of the studies were retrospective in nature and had small sample sizes. Further studies are required to elucidate the effect of neoadjuvant therapy followed by liver transplant on survival outcomes. In fact, this is already under investigation in the TRANSPHIL study (Randomized Prospective Multicentric Study: Liver Resection versus Radio-chemotherapy-Transplantation for Hilar Cholangiocarcinoma), which is expected to be completed in 2021. Furthermore, most of the studies were conducted in the West—in the East, liver transplant has not been widely adopted as a treatment of cholangiocarcinoma. Future studies exploring liver transplant as a treatment option for cholangiocarcinoma in Eastern populations would provide more evidence on the efficacy of this treatment modality.

Intrahepatic cholangiocarcinoma is a contraindication to liver transplant at most liver transplant centers around the world⁵³ because of the very poor outcomes in the early experience of liver transplant for this disease.^{54,55} A Spanish multicenter study reported a reasonable outcome with a 73% 5-year survival⁸ in a subgroup of very early intrahepatic cholangiocarcinoma (≤ 2 cm). However, the number of patients with this stage of disease was limited. In the same cohort, the outcome for combined HCC-cholangiocarcinoma had a better survival outcome, i.e. comparable with HCC patients. The authors concluded that a preoperative biopsy resulting in a diagnosis of combined HCC-cholangiocarcinoma should not exclude patients from liver transplant.

Another role of liver transplant in this group of diseases is the liver transplant for patients with primary sclerosing

Table 2. Survival Outcomes of Liver Transplant for Hilar Cholangiocarcinoma in Studies with Different Neoadjuvant and Selection Protocols

Center	Author	Year	Neoadjuvant protocol	Selection criteria	Survival
University of Cincinnati	Meyer <i>et al.</i> ⁴⁵	2000	None of the patient received neoadjuvant therapy prior to LT	Selection criteria was not adopted.	1-, 2-, 5-Year survival: 72%, 48% and 23% respectively
University of Nebraska Medical Center	Sudan <i>et al.</i> ⁴⁷	2002	6,000 cGy biliary brachytherapy Intravenous infusion of 5-fluorouracil (300 mg/m ² /day)	Patients with no evidence of extrahepatic tumor.	Survival rate was 45% with a median follow-up of 7.5 years
Multicenter in Spain	Robles <i>et al.</i> ⁴⁶	2004	None of the patient received neoadjuvant therapy prior to LT	Selection criteria was not adopted.	1-, 3-, 5-Year survival was 82%, 53%, and 30% respectively
Mayo Clinic	Darwish Murad <i>et al.</i> ⁵⁰	2012	External beam radiotherapy (99%) with sensitizing chemotherapy (5-fluorouracil) (98%) Additional brachytherapy (75%) Additional maintenance chemotherapy (oral capecitabine) (65%)	Patients outside UNOS criteria (tumor >3 cm, transperitoneal tumor biopsy or metastatic disease or with prior malignancy) was found to have significantly worse recurrence-free survival (hazard ratio, 2.98)	2-, 5-Year post transplantation recurrence-free survival rates: 78% and 65%
Europe Liver Transplant Registry	Mantel <i>et al.</i> ⁵²	2016	Patients not undergoing neoadjuvant chemotherapy were included in the study	Patients were selected according to the Mayo Clinic protocol: - Tumor size <3 cm - Absence of distant metastasis - No lymph node metastasis	5-Year survival: 59%

LT, liver transplant; UNOS, United Network of Organ Sharing.

cholangitis (PSC). Historically, PSC patients who developed cholangiocarcinoma while waiting for liver transplant had a poor prognosis and this is a relative contraindication to liver transplant in many programs. However, it was reported that the incidentally discovered tumors in the setting of PSC had good results without recurrence.^{7,56}

3. Neuroendocrine liver metastasis

Neuroendocrine tumor metastasis localized to the liver is an indication for liver transplant as it is slow-growing and has lower oncological aggressiveness compared with HCC.⁹ In view of the scarcity of donated organs and improved results of nonsurgical treatment of neuroendocrine liver metastasis, the controversy over patient selection and timing for liver transplant continues. Patients who have neuroendocrine liver metastasis usually receive multimodal treatment including a combination of surgical resection, systemic chemotherapy, radiofrequency ablation, and transarterial chemoembolization. While complete resection is considered the only curative treatment, theoretically liver transplant would be the best treatment. It would be important to exclude other extrahepatic metastases—distant lymph nodes (20% to 30%), peritoneal carcinomatosis (10% to 33%), lungs (3% to 5%), and bones (1% to 6%).⁵⁷

In a study comparing transplant with non-transplant treatment, the two groups of patients had similar 5-year overall survival but the transplant group had better 5-year disease-free survival (50% vs 34%).^{58,59} There is the criticism that comparison of patients from the date of liver transplant is unfair as these patients had already undergone other therapy;⁶⁰ comparison at the time of diagnosis or the detection of uncontrolled disease would be fairer.

A systematic review conducted by Moris *et al.*⁶¹ in 2017 summarized 64 studies evaluating the outcomes of liver transplant for neuroendocrine tumor liver metastasis. Pancreas was the found to be the most common primary tumor site. The overall recurrence rate after liver transplant ranged from 31.3% to 56.8%. The 5-year overall survival rate ranged from 50% in multicenter studies to 70.7% in aggregated data from 57 single-center studies. The authors thus concluded that liver transplant offered survival benefits to patients with diffuse neuroendocrine metastases to the liver without extrahepatic disease. They further recommended that strict selection of patients would be required in order to optimize outcomes in the face of organ shortage.

The reported prognostic factors for tumor recurrence and poor overall survival were age >50 years, symptomatic tumor, primary tumor in the pancreas or a non-gastrointestinal location, non-carcinoid tumor, high Ki-67 index, involvement of liver more than 50%, and poor tumor differentiation.^{9-11,59,62} The Milan criteria group thus suggested

the “Milan criteria in case of Neuroendocrine Tumor (Milan-NET)” in 2007.⁶² The inclusion criteria for liver transplant include confirmed histology of low-grade (G1/G2 grading according to the World Health Organization classification) neuroendocrine tumor, primary tumor removed with curative resection, metastatic diffusion to liver parenchyma $\leq 50\%$, stable disease for at least 6 months before liver transplant, and age ≤ 55 years. Application of the Milan-NET criteria resulted in 5-year and 10-year survival rates of 97% and 89% respectively.⁶³ The same study also compared transplant for neuroendocrine liver metastasis and transplant for HCC and found comparable results between them.

The data presented above suggested that stringent criteria for selection of patients with good prognostic factors for liver transplant would result in favorable long-term survival comparable with that of HCC patients. On the other hand, disease down-staging⁶⁴ and transplant delay⁶² were also proposed. From current evidence, neuroendocrine tumor is not an absolute indication for liver transplant. However, liver transplant for neuroendocrine liver metastasis was still uncommonly performed due to limited available data. In addition, most of the studies identifying prognostic variables and evaluating survival outcomes in the context of liver transplant for neuroendocrine metastasis were retrospective in nature. Future prospective studies with larger sample sizes are needed to further optimize the patient selection criteria for liver transplant for metastatic neuroendocrine tumors so that the benefit of liver transplant for this subgroup of patients can be maximized.

4. Colorectal liver metastasis

Colorectal cancer is one of the commonest cancer and a leading cause of cancer-related morbidity and death.⁶⁵ Liver metastases are commonly detected as synchronous or metachronous lesions.⁶⁶ Early attempts of liver transplant for these patients were disappointing. The first and largest published series from University of Vienna reported that the overall survival rates at 1, 3 and 5 years were 76%, 32% and 12% respectively.^{67,68} Other early studies in the 1990s also reported poor overall survival.^{69,70}

In 2013, Hagness *et al.*¹² from reported the outcomes of liver transplant for colorectal liver metastasis at Oslo University Hospital. Unlike Asian regions, Norway had a surplus of deceased donor liver grafts and the average waiting time for liver transplant was less than 1 month.^{12,13} A substantial number of liver grafts were exported to other liver transplant centers. They performed liver transplant for patients who met these three criteria: their primary tumors had been excised, their metastatic disease was confined to the liver, and they had undergone at least 6 weeks of

chemotherapy. The overall survival rates at 1, 3 and 5 years were 95%, 68% and 60% respectively. Although the overall survival results were encouraging, almost all these patients had disease recurrence after 2 years from liver transplant. Risk factors for poor survival were largest tumor diameter, carcinoembryonic antigen, time from primary surgery, and nonresponse to chemotherapy. Four years later, Toso *et al.*¹³ reported a series of 12 liver transplants for colorectal liver metastasis at four European centers. The overall survival rates at 1, 3, and 5 years were 83%, 62%, and 50% respectively, and only half of their patients had disease recurrence. Most of the patients who had synchronous metastasis received chemotherapy. All patients received a complex chemotherapy regimen and responded to chemotherapy. Predictive factors for poor disease-free survival were upfront transplant, salvage transplant, and vena cava involvement.

Liver transplant for colorectal liver metastasis is still highly controversial. With further improvement of chemotherapy, the results of treatment of colorectal liver metastasis may further improve. The role of liver transplant in the management of this disease will be redefined in the future.

5. Other neoplasms

Hepatoblastoma is the most common primary liver malignancy in children. The major treatment modalities for hepatoblastoma are chemotherapy and liver resection. However, for tumors involving all four sections, centrally located tumor which is not feasible for resection, portal vein, and hepatic vein involvement, liver transplant would be indicated.^{71,72} Long-term survival was reported to be 85%–90%.⁷³

Epithelioid hemangioendothelioma is a rare tumor of vascular origin. Some hepatic epithelioid hemangioendotheliomas behave similarly to benign hepatic hemangiomas, whereas others have a clinical course resembling highly aggressive angiosarcoma.⁷⁴ With data from United Network for Organ Sharing (UNOS), Rodriguez *et al.*⁷⁴ analyzed the outcomes in 110 hemangioendothelioma patients having liver transplant between 1987 and 2005. The 1- and 5-year patient survival rates were 80% and 64% respectively and the 1- and 5-year graft survival rates were 70% and 55% respectively.⁷⁴ A more recent study conducted by Lai *et al.*⁷⁵ demonstrated even more favorable survival outcomes. They retrospectively analyzed data from 1984 to 2014 in the European Liver Transplant Registry and found that the 1-, 5- and 10-year overall survival rates in the 149 patients having liver transplant for hepatic hemangioendothelioma were 88.6%, 79.5% and 74.4% respectively. They also identified the following three independent risk factors for recurrence: macrovascular

invasion, hilar lymph node invasion, and a wait for transplant of ≤ 120 days. These studies confirmed the value of liver transplant for patients with hemangioendothelioma. Unresectable hemangioendothelioma should therefore not be a contraindication to liver transplant. Prospective analyses are needed to determine the independent risk factors for survival of this subgroup of patients and to identify patients at risk of recurrence after liver transplant.

PATIENT FACTORS

1. Age

Advanced age was considered a relative contraindication to liver transplant as it is a major risk factor in many chronic diseases.⁷⁶ However, as the population continues to age and good antiviral treatment delayed cirrhosis process, the proportion of elderly patients requiring liver transplant is expected to increase.⁷⁷⁻⁷⁹ Compared to the young, elderly patients more commonly present with co-morbidities including cardiovascular diseases, diabetes mellitus, renal insufficiency and pulmonary diseases, which adversely affect long-term prognosis.⁸⁰ However, elderly recipients have been reported to display a lower rate of rejection with respect to immune senescence,^{81,82} which may indicate a favorable effect on graft survival.

There have been a few studies conducted to compare elderly and young transplant recipients in terms of post-operative outcomes and long-term survival.⁸¹⁻⁸⁷ The results reported were inconsistent, which was likely in part due to the heterogeneity of age cutoffs for the elderly and non-elderly (varying between 60 and 75 years). Some studies reported comparable patient and graft survival rates between the two groups,^{82,83,85} while some reported significantly worse survival in the elderly group.^{81,84,86,87}

One of the studies reporting inferior outcomes in elderly transplant recipients was a large retrospective study conducted by the University of California. The study compared 3,711 transplant recipients aged ≥ 60 years and 11,966 recipients younger than 60 years.⁸⁷ It was found that age ≥ 70 years was independently associated with an increased risk of graft loss (hazard ratio, 1.65; 95% confidence interval, 1.08 to 1.82; $p < 0.001$). However, the increased risk was attenuated in elderly patients with a MELD score < 28 . It was thus concluded that patients should not be excluded solely because of age. Similarly, preoperative intensive care unit admission,⁸⁵ fulminant hepatic failure,⁸⁵ pretransplant hospital admission⁸⁶ and high bilirubin level⁸⁶ were identified as independent risk factors for inferior outcomes in elderly patients.

Currently in the literature, the results of studies of liver

transplant for the elderly are inconsistent. However, almost all studies concluded that age alone should not be an exclusion factor for liver transplant. For optimization of patient selection and graft allocation, further prospective studies should be conducted to identify the risk factors in elderly patients.

2. Co-morbidity

Patients with failure of another organ in addition to the liver may need a transplant simultaneous with liver transplant. Combined liver and kidney transplantation was probably the commonest combined organ transplant performed (6.8% of all liver transplants in the United States).¹⁶ Hepatorenal syndrome together with preexisting kidney disease, are common indications for combined liver and kidney transplant; these include chronic glomerulonephritis, diabetic nephropathy, polycystic kidney disease, calcineurin inhibitor toxicity and hypertensive kidney disease.⁸⁸ A study by Schmitt *et al.*⁸⁹ demonstrated that patients with renal failure on hemodialysis had more survival benefit from combined liver-kidney transplants when compared with patients with renal failure but not on hemodialysis. For patients with renal failure but not on hemodialysis, there was no increase in survival when comparing combined liver-kidney transplants to liver transplants alone.

A well-established advantage of combined liver and kidney transplant is an immunoprotective effect of the transplanted kidney from the liver allograft when both organs come from the same donor.^{90,91} The possible mechanism has not been clearly elucidated, but it has been suggested that the liver absorbs lymphocytotoxic antibodies, promotes antibody phagocytosis by Kupffer cells, and secretes soluble human leukocyte antigens. A pretransplant cross-match is not routinely performed and cases of conversion of a positive to a negative cross-match posttransplant have been described. The most common indication for combined liver and kidney transplant in children is inherited hepatic metabolic abnormalities such as primary hyperoxaluria.⁹² Kitajima *et al.*⁹³ reported that a sequential liver-kidney transplant from a single living donor achieved an excellent overall survival rate of 92.3% in 10 years.

Combined heart and liver transplant was described for patients with familial amyloid polyneuropathy (FAP). In this group of patients, the liver produces the majority of the transthyretin that is involved in the cause of amyloid deposition.⁹⁴ Cardiac cirrhosis is the most common hepatic diagnosis in patients with coronary heart disease.¹⁷ Other indications of combined heart and liver transplant include familial hypercholesterolemia, beta-thalassemia,⁹⁵ hemochromatosis,⁹⁶ alcoholic cardiomyopathy, cryptogenic cirrhosis with underlying cardiomyopathy and glycogen

storage disease.⁹⁷ Combined liver and lung transplantation were reported to be performed in cystic fibrosis patients.⁹⁸ Together with the experience and advancement, the use of liver transplant in these patients are likely to be expanded.

3. Expanding graft availability in low deceased donor rate regions

Despite high demand, a severe shortage of suitable allografts limits the use of liver transplant for the treatment of different etiologies of liver diseases. The condition in Asian centers including Hong Kong is different from Scandinavian countries described—having a surplus in liver grafts is a kind of luxury. Expanding the indications for liver transplant affects patients who were already on list. Resistance would be encountered if the outcome of new indications were not proven to be good enough. On the other hand, living donor liver transplant and multiple other strategies were developed to further increase organ supply. Close relatives are the commonest living donor but their ABO blood group may not be compatible. ABO-incompatible living donor liver transplant protocols with the use of rituximab and plasma exchange were reported by multiple living donor liver transplant centers.⁹⁹⁻¹⁰¹ Donor exchange programs were also aimed at resolving the incompatible relative problem.^{102,103} Domino liver transplant, with the example of FAP graft, were reported to have comparable short term results with deceased donor liver transplant.¹⁰⁴ However, the de novo development of FAP within various periods has been described.¹⁰⁵

Another strategy to expand the donor pool is utilization of extended criteria donor grafts, e.g. donation after circulatory death (DCD),¹⁰⁶ steatotic,¹⁰⁷ and elderly grafts,^{108,109} etc. Liver transplant service could only be expanded with the expansion of indication together with graft availability.

Although the number of cadaveric organ donations has not increased in most Asian places, South Korea has recently succeeded in increasing the rate of organ donation by introducing several systems, such as incentive programs, an organ procurement organization, a donor registry, and a system to facilitate potential donor referral.¹¹⁰ With these measures, the number of braindead donors increased from 50 in 2003 to 367 in 2013. This experience may help other Asian regions to improve their organ donation rates.¹¹¹

4. Extension of deceased donor criteria

Extension of deceased donor criteria may be a potential method to expand liver transplant indications. Liver grafts from DCD are a potential source of organ growth in the West. Croome *et al.*¹¹² compared DCD and donation after brain death (DBD) in terms of liver transplant recipient survival. The 1-, 3- and 5-year survival rates were 92.3%,

86.1% and 80.3% respectively in the DCD group and 92.3%, 85.1% and 79.5% respectively in the DBD group ($p=0.27$). The use of organs from DCD may be a method to alleviate organ shortages in Asian regions. DCD is still limited in Asia. However, in Mainland China, DCD has been the sole legal source of donor organs since 2015. A study found that DCD was associated with a higher risk of early allograft dysfunction.¹¹³ Future studies are required to evaluate the outcomes of DCD liver transplant and explore the possibility of adopting DCD grafts as a method of increasing graft supply in Asia.

CONCLUSION

The scope of indications for liver transplant has been gradually expanding over the decades. Going forward, further development of preoperative noninvasive predictors in tumor, patient and even donor factors is needed to identify patients at risk of poor outcomes. Stringently relaxed criteria for liver transplant will be the way to go. The significance of development of tools that can accurately predict outcomes lies not only in patient consultation and management but also in implementation of policies and guidelines in the future.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ORCID

Kevin Ka-Wan Chu

<https://orcid.org/0000-0001-7371-7633>

Kelly Hiu-Ching Wong

<https://orcid.org/0000-0003-3487-0197>

Kenneth Siu-Ho Chok

<https://orcid.org/0000-0001-7921-3807>

REFERENCES

1. Chu KK, Chan SC, Sharr WW, Chok KS, Dai WC, Lo CM. Low-volume deceased donor liver transplantation alongside a strong living donor liver transplantation service. *World J Surg* 2014;38:1522-1528.
2. Jones PD, Hayashi PH, Barritt AS 4th. Liver transplantation in 2013: challenges and controversies. *Minerva Gastroen-*

- terol Dietol 2013;59:117-131.
3. Hashikura Y, Makuuchi M, Kawasaki S, et al. Successful living-related partial liver transplantation to an adult patient. *Lancet* 1994;343:1233-1234.
 4. Lo CM, Fan ST, Liu CL, et al. Extending the limit on the size of adult recipient in living donor liver transplantation using extended right lobe graft. *Transplantation* 1997;63:1524-1528.
 5. Strong RW, Lynch SV, Ong TH, Matsunami H, Koido Y, Balderson GA. Successful liver transplantation from a living donor to her son. *N Engl J Med* 1990;322:1505-1507.
 6. Starzl TE, Groth CG, Brettschneider L, et al. Orthotopic homotransplantation of the human liver. *Ann Surg* 1968;168:392-415.
 7. De Vreede I, Steers JL, Burch PA, et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoradiation for cholangiocarcinoma. *Liver Transpl* 2000;6:309-316.
 8. Sapisochin G, Rodríguez de Lope C, Gastaca M, et al. "Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients? *Am J Transplant* 2014;14:660-667.
 9. Gedaly R, Daily MF, Davenport D, et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. *Arch Surg* 2011;146:953-958.
 10. Le Treut YP, Grégoire E, Klempnauer J, et al. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. *Ann Surg* 2013;257:807-815.
 11. Nguyen NT, Harring TR, Goss JA, O'Mahony CA. Neuroendocrine liver metastases and orthotopic liver transplantation: the US experience. *Int J Hepatol* 2011;2011:742890.
 12. Hagness M, Foss A, Line PD, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. *Ann Surg* 2013;257:800-806.
 13. Toso C, Pinto Marques H, Andres A, et al. Liver transplantation for colorectal liver metastasis: survival without recurrence can be achieved. *Liver Transpl* 2017;23:1073-1076.
 14. Carrion AF, Aye L, Martin P. Patient selection for liver transplantation. *Expert Rev Gastroenterol Hepatol* 2013;7:571-579.
 15. Couetil JP, Houssin DP, Soubrane O, et al. Combined lung and liver transplantation in patients with cystic fibrosis: a 4 1/2-year experience. *J Thorac Cardiovasc Surg* 1995;110:1415-1422.
 16. Papafragkakis H, Martin P, Akalin E. Combined liver and kidney transplantation. *Curr Opin Organ Transplant* 2010;15:263-268.
 17. Bryant R 3rd, Rizwan R, Zafar F, et al. Contemporary outcomes of combined heart-liver transplant in patients with congenital heart disease. *Transplantation* 2018;102:e67-e73.
 18. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996;334:693-699.
 19. Mazzaferro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. *Liver Transpl* 2011;17 Suppl 2:S44-S57.
 20. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. *Hepatology* 2001;33:1394-1403.
 21. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. *Am J Transplant* 2007;7:2587-2596.
 22. Patel SS, Arrington AK, McKenzie S, et al. Milan criteria and UCSF criteria: a preliminary comparative study of liver transplantation outcomes in the United States. *Int J Hepatol* 2012;2012:253517.
 23. Fan J, Yang GS, Fu ZR, et al. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. *J Cancer Res Clin Oncol* 2009;135:1403-1412.
 24. Lee SG, Hwang S, Moon DB, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. *Liver Transpl* 2008;14:935-945.
 25. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. *Lancet Oncol* 2009;10:35-43.
 26. Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. *Dig Dis* 2007;25:310-312.
 27. Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. *Transplantation* 2008;85:1726-1732.
 28. Xu X, Lu D, Ling Q, et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. *Gut* 2016;65:1035-1041.
 29. Xu X, Zheng SS, Liang TB, et al. Orthotopic liver transplantation for patients with hepatocellular carcinoma complicated by portal vein tumor thrombi. *Hepatobiliary Pancreat Dis Int* 2004;3:341-344.
 30. Choi HJ, Kim DG, Na GH, et al. The clinical outcomes of patients with portal vein tumor thrombi after living donor liver transplantation. *Liver Transpl* 2017;23:1023-1031.
 31. Choi JY, Yu JI, Park HC, et al. The possibility of radiotherapy as downstaging to living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus.

- Liver Transpl 2017;23:545-551.
32. Lee KW, Suh SW, Choi Y, et al. Macrovascular invasion is not an absolute contraindication for living donor liver transplantation. *Liver Transpl* 2017;23:19-27.
 33. Ito T, Takada Y, Ueda M, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. *Liver Transpl* 2007;13:1637-1644.
 34. Kim JM, Kwon CH, Joh JW, et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma. *Transplant Proc* 2014;46:726-729.
 35. Shimamura T, Akamatsu N, Fujiyoshi M, et al. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule. A retrospective study. *Transpl Int* 2019;32:356-368.
 36. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. *Liver Transpl* 2014;20:945-951.
 37. Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. *Liver Transpl* 2015;21:1142-1152.
 38. Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. *Hepatology* 2015;61:1968-1977.
 39. Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. *Best Pract Res Clin Gastroenterol* 2015;29:221-232.
 40. Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. *Clin Gastroenterol Hepatol* 2013;11:13-21.
 41. Hu HJ, Mao H, Shrestha A, et al. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: a single-institution experience in China. *World J Gastroenterol* 2016;22:2601-2610.
 42. DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. *Ann Surg* 2007;245:755-762.
 43. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. *Ann Surg* 2001;234:507-517.
 44. Kimura N, Young AL, Toyoki Y, et al. Radical operation for hilar cholangiocarcinoma in comparable Eastern and Western centers: outcome analysis and prognostic factors. *Surgery* 2017;162:500-514.
 45. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. *Transplantation* 2000;69:1633-1637.
 46. Robles R, Figueras J, Turrión VS, et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. *Ann Surg* 2004;239:265-271.
 47. Sudan D, DeRoover A, Chinnakotla S, et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. *Am J Transplant* 2002;2:774-779.
 48. Heimbach JK, Gores GJ, Nagorney DM, Rosen CB. Liver transplantation for perihilar cholangiocarcinoma after aggressive neoadjuvant therapy: a new paradigm for liver and biliary malignancies? *Surgery* 2006;140:331-334.
 49. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. *Ann Surg* 2005;242:451-458.
 50. Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. *Gastroenterology* 2012;143:88-98.
 51. Hong JC, Petrowsky H, Kaldas FM, et al. Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma. *J Am Coll Surg* 2011;212:514-520.
 52. Mantel HT, Westerkamp AC, Adam R, et al. Strict selection alone of patients undergoing liver transplantation for hilar cholangiocarcinoma is associated with improved survival. *PLoS One* 2016;11:e0156127.
 53. Razumilava N, Gores GJ. Cholangiocarcinoma. *Lancet* 2014;383:2168-2179.
 54. O'Grady JG, Polson RJ, Rolles K, Calne RY, Williams R. Liver transplantation for malignant disease: results in 93 consecutive patients. *Ann Surg* 1988;207:373-379.
 55. Ringe B, Wittekind C, Bechstein WO, Bunzendahl H, Pichlmayr R. The role of liver transplantation in hepatobiliary malignancy: a retrospective analysis of 95 patients with particular regard to tumor stage and recurrence. *Ann Surg* 1989;209:88-98.
 56. Goss JA, Shackleton CR, Farmer DG, et al. Orthotopic liver transplantation for primary sclerosing cholangitis: a 12-year single center experience. *Ann Surg* 1997;225:472-481.
 57. de Mestier L, Lardièrre-Deguelte S, Brix H, et al. Updating the surgical management of peritoneal carcinomatosis in patients with neuroendocrine tumors. *Neuroendocrinology* 2015;101:105-111.
 58. Coppa J, Pulvirenti A, Schiavo M, et al. Resection versus transplantation for liver metastases from neuroendocrine tumors. *Transplant Proc* 2001;33:1537-1539.
 59. Frilling A, Malago M, Weber F, et al. Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients. *Liver Transpl* 2006;12:1089-1096.
 60. Fan ST, Le Treut YP, Mazzaferro V, et al. Liver transplantation for neuroendocrine tumour liver metastases. *HPB (Ox-*

- ford) 2015;17:23-28.
61. Moris D, Tsilimigras DI, Ntanasis-Stathopoulos I, et al. Liver transplantation in patients with liver metastases from neuroendocrine tumors: a systematic review. *Surgery* 2017;162:525-536.
 62. Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? *J Hepatol* 2007;47:460-466.
 63. Mazzaferro V, Sposito C, Coppa J, et al. The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors. *Am J Transplant* 2016;16:2892-2902.
 64. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. *J Clin Oncol* 2008;26:3063-3072.
 65. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *Eur J Cancer* 2013;49:1374-1403.
 66. Page AJ, Cosgrove DC, Herman JM, Pawlik TM. Advances in understanding of colorectal liver metastasis and implications for the clinic. *Expert Rev Gastroenterol Hepatol* 2015;9:245-259.
 67. Moris D, Tsilimigras DI, Chakedis J, et al. Liver transplantation for unresectable colorectal liver metastases: a systematic review. *J Surg Oncol* 2017;116:288-297.
 68. Mühlbacher F, Huk I, Steininger R, et al. Is orthotopic liver transplantation a feasible treatment for secondary cancer of the liver? *Transplant Proc* 1991;23(1 Pt 2):1567-1568.
 69. Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. *Surgery* 1991;110:726-734.
 70. Hoti E, Adam R. Liver transplantation for primary and metastatic liver cancers. *Transpl Int* 2008;21:1107-1117.
 71. Meyers RL, Tiao GM, Dunn SP, Langham MR Jr. Liver transplantation in the management of unresectable hepatoblastoma in children. *Front Biosci (Elite Ed)* 2012;4:1293-1302.
 72. Gupta AA, Gerstle JT, Ng V, et al. Critical review of controversial issues in the management of advanced pediatric liver tumors. *Pediatr Blood Cancer* 2011;56:1013-1018.
 73. Hackl C, Schlitt HJ, Kirchner GI, Knoppke B, Loss M. Liver transplantation for malignancy: current treatment strategies and future perspectives. *World J Gastroenterol* 2014;20:5331-5344.
 74. Rodriguez JA, Becker NS, O'Mahony CA, Goss JA, Aloia TA. Long-term outcomes following liver transplantation for hepatic hemangioendothelioma: the UNOS experience from 1987 to 2005. *J Gastrointest Surg* 2008;12:110-116.
 75. Lai Q, Feys E, Karam V, et al. Hepatic epithelioid hemangioendothelioma and adult liver transplantation: proposal for a prognostic score based on the analysis of the ELTR-ELITA registry. *Transplantation* 2017;101:555-564.
 76. National Institutes of Health Consensus Development Conference Statement on the Clinical Applications of Biomaterials. November 1-3, 1982. *Artif Organs* 1983;7:260-265.
 77. Emre S, Mor E, Schwartz ME, et al. Liver transplantation in patients beyond age 60. *Transplant Proc* 1993;25(1 Pt 2):1075-1076.
 78. Oezcelik A, Dayangac M, Guler N, et al. Living donor liver transplantation in patients 70 years or older. *Transplantation* 2015;99:1436-1440.
 79. Taner CB, Ung RL, Rosser BG, Aranda-Michel J. Age is not a contraindication for orthotopic liver transplantation: a single institution experience with recipients older than 75 years. *Hepatol Int* 2012;6:403-407.
 80. Petrowsky H, Rana A, Kaldas FM, et al. Liver transplantation in highest acuity recipients: identifying factors to avoid futility. *Ann Surg* 2014;259:1186-1194.
 81. Wilson GC, Quillin RC 3rd, Wima K, et al. Is liver transplantation safe and effective in elderly (≥ 70 years) recipients? A case-controlled analysis. *HPB (Oxford)* 2014;16:1088-1094.
 82. Ikegami T, Bekki Y, Imai D, et al. Clinical outcomes of living donor liver transplantation for patients 65 years old or older with preserved performance status. *Liver Transpl* 2014;20:408-415.
 83. Aduen JF, Sujay B, Dickson RC, et al. Outcomes after liver transplant in patients aged 70 years or older compared with those younger than 60 years. *Mayo Clin Proc* 2009;84:973-978.
 84. Gil E, Kim JM, Jeon K, et al. Recipient age and mortality after liver transplantation: a population-based cohort study. *Transplantation* 2018;102:2025-2032.
 85. Kuramitsu K, Egawa H, Keeffe EB, et al. Impact of age older than 60 years in living donor liver transplantation. *Transplantation* 2007;84:166-172.
 86. Levy MF, Somasundar PS, Jennings LW, et al. The elderly liver transplant recipient: a call for caution. *Ann Surg* 2001;233:107-113.
 87. Sharpton SR, Feng S, Hameed B, Yao F, Lai JC. Combined effects of recipient age and model for end-stage liver disease score on liver transplantation outcomes. *Transplantation* 2014;98:557-562.
 88. Chava SP, Singh B, Zaman MB, Rela M, Heaton ND. Current indications for combined liver and kidney transplantation in adults. *Transplant Rev (Orlando)* 2009;23:111-119.
 89. Schmitt TM, Kumer SC, Al-Osaimi A, et al. Combined liver-kidney and liver transplantation in patients with renal failure outcomes in the MELD era. *Transpl Int* 2009;22:876-883.
 90. Rana A, Robles S, Russo MJ, et al. The combined organ effect: protection against rejection? *Ann Surg* 2008;248:871-879.
 91. Simpson N, Cho YW, Cicciarelli JC, Selby RR, Fong TL. Comparison of renal allograft outcomes in combined liver-kidney transplantation versus subsequent kidney transplan-

- tation in liver transplant recipients: analysis of UNOS Database. *Transplantation* 2006;82:1298-1303.
92. Chava SP, Singh B, Pal S, Dhawan A, Heaton ND. Indications for combined liver and kidney transplantation in children. *Pediatr Transplant* 2009;13:661-669.
 93. Kitajima K, Ogawa Y, Miki K, et al. Longterm renal allograft survival after sequential liver-kidney transplantation from a single living donor. *Liver Transpl* 2017;23:315-323.
 94. Siddiqi OK, Ruberg FL. Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment. *Trends Cardiovasc Med* 2018;28:10-21.
 95. Olivieri NF, Liu PP, Sher GD, et al. Brief report: combined liver and heart transplantation for end-stage iron-induced organ failure in an adult with homozygous beta-thalassemia. *N Engl J Med* 1994;330:1125-1127.
 96. Robinson MR, Al-Kindi SG, Oliveira GH. Heart and heart-liver transplantation in patients with hemochromatosis. *Int J Cardiol* 2017;244:226-228.
 97. Beal EW, Mumtaz K, Hayes D Jr, Whitson BA, Black SM. Combined heart-liver transplantation: indications, outcomes and current experience. *Transplant Rev (Orlando)* 2016;30:261-268.
 98. Arnon R, Annunziato RA, Miloh T, et al. Liver and combined lung and liver transplantation for cystic fibrosis: analysis of the UNOS database. *Pediatr Transplant* 2011;15:254-264.
 99. Ikegami T, Yoshizumi T, Soejima Y, Uchiyama H, Shirabe K, Maehara Y. Feasible usage of ABO incompatible grafts in living donor liver transplantation. *Hepatobiliary Surg Nutr* 2016;5:91-97.
 100. Lee CF, Cheng CH, Wang YC, et al. Adult living donor liver transplantation across ABO-incompatibility. *Medicine (Baltimore)* 2015;94:e1796.
 101. Song GW, Lee SG, Hwang S, et al. ABO-incompatible adult living donor liver transplantation under the desensitization protocol with rituximab. *Am J Transplant* 2016;16:157-170.
 102. Chan SC, Lo CM, Yong BH, Tsui WJ, Ng KK, Fan ST. Paired donor interchange to avoid ABO-incompatible living donor liver transplantation. *Liver Transpl* 2010;16:478-481.
 103. Jung DH, Hwang S, Ahn CS, et al. Section 16. Update on experience in paired-exchange donors in living donor liver transplantation for adult patients at ASAN Medical Center. *Transplantation* 2014;97 Suppl 8:S66-S69.
 104. Marín-Gómez LM, Gómez-Bravo MA, Barrera-Pulido L, et al. Outcomes of domino liver transplantation: a single institution's experience. *Transplant Proc* 2010;42:644-646.
 105. Stangou AJ, Heaton ND, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. *N Engl J Med* 2005;352:2356.
 106. Reich DJ, Mulligan DC, Abt PL, et al. ASTS recommended practice guidelines for controlled donation after cardiac death organ procurement and transplantation. *Am J Transplant* 2009;9:2004-2011.
 107. Wong TC, Fung JY, Chok KS, et al. Excellent outcomes of liver transplantation using severely steatotic grafts from brain-dead donors. *Liver Transpl* 2016;22:226-236.
 108. Akamatsu N, Sugawara Y, Tamura S, et al. Impact of live donor age (≥ 50) on liver transplantation. *Transplant Proc* 2007;39:3189-3193.
 109. Tanemura A, Mizuno S, Wada H, Yamada T, Nobori T, Isaji S. Donor age affects liver regeneration during early period in the graft liver and late period in the remnant liver after living donor liver transplantation. *World J Surg* 2012;36:1102-1111.
 110. Lee SD, Kim JH. Changes in the organ procurement system in South Korea: effects on brain-dead donor numbers. *Transplant Proc* 2009;41:3551-3555.
 111. Soyama A, Eguchi S. The current status and future perspectives of organ donation in Japan: learning from the systems in other countries. *Surg Today* 2016;46:387-392.
 112. Croome KP, Lee DD, Perry DK, et al. Comparison of long-term outcomes and quality of life in recipients of donation after cardiac death liver grafts with a propensity-matched cohort. *Liver Transpl* 2017;23:342-351.
 113. Zhou J, Wei Q, Zheng S, Xu X. Early allograft dysfunction after liver transplantation with donation after cardiac death donors. *Hepatobiliary Surg Nutr* 2019;8:566-568.
 114. Unek T, Karademir S, Arslan NC, et al. Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma. *World J Gastroenterol* 2011;17:4206-4212.
 115. Togashi J, Akamatsu N, Kokudo N. Living donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital. *Hepatobiliary Surg Nutr* 2016;5:399-407.
 116. Bonadio I, Colle I, Geerts A, et al. Liver transplantation for hepatocellular carcinoma comparing the Milan, UCSF, and Asan criteria: long-term follow-up of a Western single institutional experience. *Clin Transplant* 2015;29:425-433.
 117. de Ataide EC, Garcia M, Mattosinho TJ, Almeida JR, Escanhoela CA, Boin IE. Predicting survival after liver transplantation using up-to-seven criteria in patients with hepatocellular carcinoma. *Transplant Proc* 2012;44:2438-2440.
 118. Kaido T, Ogawa K, Mori A, et al. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. *Surgery* 2013;154:1053-1060.
 119. Lei J, Yan L. Comparison between living donor liver transplantation recipients who met the Milan and UCSF criteria after successful downstaging therapies. *J Gastrointest Surg* 2012;16:2120-2125.